Seikagaku reported FY 2Q19 revenue of JPY ¥7,906MM (USD $71.4MM), +12.5% vs. 2Q18.
U.S. viscosupplement sales had sizeable volume increases due to qualification for preferential reimbursement status with multiple insurance carriers and well as conversion of competitive accounts
Sales of five injection treatment SUPARTZ FX saw volume declines due to U.S. trending toward favoring single treatment products
Sales volume grew in China but was offset by currency headwinds
ORTHOWORLD projects Seikagaku full calendar year 2019 revenue of $275.6MM, +7.7% vs. 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
2Q19
2Q18
$ Chg
% Chg
Orthobiologics
$71.4
$63.5
$7.9
12.5%
1H19
1H18
$ Chg
% Chg
Orthobiologics
$140.4
$128.7
$11.7
9.1%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported FY 2Q19 revenue of JPY ¥7,906MM (USD $71.4MM), +12.5% vs. 2Q18.
U.S. viscosupplement sales had sizeable volume increases due to qualification for preferential reimbursement status with multiple insurance carriers and well as conversion of competitive accounts Sales of five injection treatment SUPARTZ FX saw volume...
Seikagaku reported FY 2Q19 revenue of JPY ¥7,906MM (USD $71.4MM), +12.5% vs. 2Q18.
U.S. viscosupplement sales had sizeable volume increases due to qualification for preferential reimbursement status with multiple insurance carriers and well as conversion of competitive accounts
Sales of five injection treatment SUPARTZ FX saw volume declines due to U.S. trending toward favoring single treatment products
Sales volume grew in China but was offset by currency headwinds
ORTHOWORLD projects Seikagaku full calendar year 2019 revenue of $275.6MM, +7.7% vs. 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
2Q19
2Q18
$ Chg
% Chg
Orthobiologics
$71.4
$63.5
$7.9
12.5%
1H19
1H18
$ Chg
% Chg
Orthobiologics
$140.4
$128.7
$11.7
9.1%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
